SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H....
Transcript of SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H....
![Page 1: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/1.jpg)
SAVR in the Era of TAVR
Vinod H. Thourani, MD
Bernie Marcus Chief of Cardiovascular Surgery
Marcus Heart and Vascular Center and Valve Center
Piedmont Heart Institute
Atlanta, GA, USA
PAR Annual Course
Athens, GA
February, 2020
![Page 2: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/2.jpg)
Disclosures
• Abbott Vascular
– National Co-PI: Mitral in MAC Arm (SUMMIT trial)
– Advisor, Research
• Boston Scientific
– National Co-PI: REPRISE IV trial
– Steering Committee: ACURATE trial
– Advisor, Research
• Cryolife
– Executive Committee, PROACT X trial
• Edwards Lifesciences
– National Co-PI: CLASP IIF
– National PI: Harpoon Trial
• Gore Vascular
– Advisory board
• JenaValve
– Advisory Board
– National Co-PI: EFS trial
![Page 3: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/3.jpg)
4,6668,946
16,301
24,819
38,276
51,303
59,293
255 499 1318 2358 3153 3732
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
2012 2013 2014 2015 2016 2017 2018
TVT Registry Datamart Data as of 6/6/19
TVT RegistryTAVR and TAVR ViV Procedures
![Page 4: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/4.jpg)
SAVR and TAVR Volumes
29,829 30,275
28,67926,032
25,274
16,308
24,820
38,240
51,271
59,527
51,717
18385 18103 1758515781 15855
2565 2560724
2485 26700
10,000
20,000
30,000
40,000
50,000
60,000
70,000
2014 2015 2016 2017 2018 2019 Q1-3
SAVR TAVR AVR/CABG AVR/MVR
![Page 5: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/5.jpg)
TAVRMedian LOS in Days
(25th and 75th percentiles)10 10
9
8
6
5
44 4 4
3
2 2 2
67
6
4
32
2
0
2
4
6
8
10
12
2012 2013 2014 2015 2016 2017 2018 Q1
![Page 6: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/6.jpg)
TAVR MortalityIn-Hospital, 30 Day, and One Year Mortality
5.7%5.2% 4.1%
2.9% 2% 1.7% 1.6%
7.5% 7%6%
4.4%3.2% 2.9% 2.8%
26.4%
21.8% 21.6%
18.2%
15.3%13.9%
0%
5%
10%
15%
20%
25%
30%
2012 2013 2014 2015 2016 2017 2018 Q1
In Hospital 30 Day 1yr (CMS linked data)
![Page 7: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/7.jpg)
TAVR StrokeIn-Hospital, 30 Day, and One Year Stroke
2.2%2.0% 2.2% 2.0%
1.8% 1.8% 1.8%
2.8% 2.7% 2.8%2.5% 2.4% 2.5% 2.5%
3.9% 3.9%4.2% 4.3% 4.2%
3.9%
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
4.0%
4.5%
5.0%
2012 2013 2014 2015 2016 2017 2018 Q1
In Hospital 30 Day One Yr CMS linked
![Page 8: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/8.jpg)
TAVRNew (No PPM pre TAVR)
In Hospital and 30 Day Pacemaker
9.1%
12.9% 13.2%
11.0%
9.9% 9.6%
10.9%
14.8% 15.0%
13.0%12.1% 12.4%
0%
2%
4%
6%
8%
10%
12%
14%
16%
2013 2014 2015 2016 2017 2018 Q1In Hospital Pacemaker 30 Day Pacemaker
![Page 9: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/9.jpg)
TAVR Guidelines (2017)The New AHA/ACC Focused Update
![Page 10: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/10.jpg)
nn
nn
![Page 11: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/11.jpg)
![Page 12: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/12.jpg)
Primary Endpoint
0 3 6 9 12
496 475 467 462 456454 408 390 381 377
Number at risk:
TAVRSurgery
Months after Procedure
451374
TAVRSurgery
Psuperiority= 0.001
HR [95% CI] =
0.54 [0.37, 0.79]
Death
, S
troke, or
Rehosp
(%)
Pnon-inferiority< 0.001
Upper 95% CI of
risk diff = -2.5%
8.5%9.3%
15.1%
4.2%
0
10
20
![Page 13: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/13.jpg)
All StrokeA
ll S
troke (
%)
491 491 489 487454 435 427 423 421
484417
Months from ProcedureNumber at risk:
HR [95% CI] =
0.38 [0.15, 1.00]
496TAVRSurgery
1.2%
2.4% 3.1%
P = 0.04
0
10
20
0.6%0 3 6 9 12
TAVRSurgery
![Page 14: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/14.jpg)
![Page 15: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/15.jpg)
15
0%
2%
4%
6%
8%
10%
0 1 2 3 4 5 6 7 8 9 10 11 12
TAVR
SAVR
Dea
th o
r D
isab
ling
Stro
ke (
%)
Months
30 Days 2.50.7
1 Year4.6 2.7
No. at risk
TAVR 725 718 648 435
SAVR 678 656 576 366
K-M All-Cause Mortality or Disabling Stroke at 1 Year
Log-rank P = 0.065
![Page 16: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/16.jpg)
0%
2%
4%
6%
0 1 2 3 4 5 6 7 8 9 10 11 12
K-M Disabling Stroke at 1 Year
Log-rank P = 0.024
No. at risk
TAVR 725 720 648 435
SAVR 678 656 576 366
Months
Dis
ablin
g St
roke
(%
)
1 Year
2.30.7
![Page 17: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/17.jpg)
Low-Risk Trials: TBD
• Low risk TAVR RCTs did not include young
or BAV patients
• More data is required on:
• TAVR in BAV
• Long-term effects of pacemaker / LBB
• Long-term effects of mild AI
• Consequences of leaflet thrombosis
• TAVR durability
![Page 18: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/18.jpg)
Excellent SAVR Outcomes in
Low Risk AS Patients: STS Database
80% of patients low risk (STS score < 4%)
Thourani et al, Ann Thorac Surg, 2015;99:55-61
![Page 19: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/19.jpg)
Obstacles to TAVR Expansion
• Anatomical Obstacles
–Bicuspid
–LVOT calcium
• Durability / Thrombus
• Conducting system injury
• Paravalvular regurgitation
• Cost
![Page 20: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/20.jpg)
Bicuspid AV Patients!
Courtesy of Joerg Kempfert
![Page 21: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/21.jpg)
Anatomical Differences
for TAVR vs SAVR
![Page 22: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/22.jpg)
The PARTNER 2A TrialStudy Design
Primary Endpoint: All-Cause Mortality or Disabling Stroke at 2 Years
Randomized Patients
n = 2,032Enrollment Dates: Dec. 2011 – Nov. 2013
Symptomatic Severe Aortic Stenosis
ASSESSMENT by Heart Valve Team
Operable (STS ≥ 4%)
TF TAVR
(n = 775)
Surgical AVR
(n = 775)VS.
ASSESSMENT:
Transfemoral Access
1:1 Randomization (n = 1,550)
Yes No
Transfemoral (TF)
TA/TAo TAVR
(n = 236)
Surgical AVR
(n = 246)VS.
1:1 Randomization (n = 482)
Transapical (TA) / TransAortic
(TAo)
![Page 23: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/23.jpg)
0
0.5
1
1.5
2
Baseline 30 Days 1 Year 2 Years 3 Years 4 Years 5 Years
Ao
rtic
Va
lve
Are
a (
cm
2)
899 827 695 572 365 289861 726 590 490 349 259
No. of Echos:
TAVRSurgery
468413
1.67
1.47
1.57
1.42
1.54
1.40
1.54
1.39 1.36
1.48 1.50
1.37
0.700.70
P = 0.001
TAVR
Surgery
Mean ± SE
Aortic Valve Area
VI Population
Thourani, TCT, 2019
![Page 24: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/24.jpg)
0
10
20
30
40
50
Baseline 30 Days 1 Year 2 Years 3 Years 4 Years 5 Years
45.0
44.7
P = 0.23
9.7
10.9 11.5
10.7
11.7
10.8
11.7
10.8
11.4
11.2 10.8
11.4
No. of Echos:
TAVRSurgery
959916
890788
751633
633538
522453
405377
323288
TAVR
Surgery
Mean ± SE
Me
an
Gra
die
nt (m
mH
g)
Mean Aortic Valve Gradient
VI Population
![Page 25: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/25.jpg)
n (%)TAVR
(n = 21)
Surgery
(n = 5)
Reasons for Re-intervention*
Stenosis 10 (48) 0
Regurgitation 11 (52)* 1 (20)
Endocarditis 0 4 (80)
Treatment modality
Repeat TAVR (TAVR-in-TAVR) 17 (81) 0
Valvuloplasty 1 (5) 0
Surgery 3 (14) 5 (100)
In-Hospital Mortality 1 (5) 3 (60)
Aortic Valve Re-intervention
Incidence and Details
*TAVR cohort: 9/10 stenosis cases and 2/11 regurgitation cases were due to SVD. In the SAVR cohort, 1 case of
regurgitation was due to SVD.
![Page 26: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/26.jpg)
P = 0.003
HR: 3.93 [95% CI: 1.48, 10.43]
99.496.8
Fre
ed
om
fro
m R
e-i
nte
rve
nti
on
(%
)
0
25
50
75
100
Months0 12 24 36 48 60
1,011 860 805 699 591 3121,021 802 730 651 565 301
No. at risk:
TAVRSurgery
TAVR
Surgery
Freedom from Aortic Valve Re-intervention
ITT Population
![Page 27: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/27.jpg)
Mod/Severe
Mild
None or trace
0
20
40
60
80
100
TAVR Surgery TAVR Surgery TAVR Surgery
30 Days 2 Years 5 Years
3.8
22.5
0.52.8 8.2
26.9
0.63.5 6.5
26.8
0.45.9
Pa
tie
nts
(%
)
872 609 310757 516 272
73.7
96.7
64.9
95.9
66.8
93.8
No. of Echos:
Paravalvular Regurgitation
VI PopulationP < 0.001 TAVR vs SAVR in all PVR categories at all FU times
![Page 28: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/28.jpg)
Death From Any Cause by PVR Severity
VI TAVR Population
Overall Log-Rank P < 0.001
Mild vs none-trace
P = 0.07
Mild vs mod-severe
P = 0.007
41.1
48.7
64.8
De
ath
(%
)
0
20
40
60
80
Months0 12 24 36 48 60
643 592 557 495 427 225
196 178 170 143 120 6333 25 20 16 11 5
No. at risk:None-trace
MildMod-severe
![Page 29: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/29.jpg)
HR: 0.87 [95% CI: 0.62, 1.22] HR: 1.11 [95% CI: 0.87, 1.42]
12.4
13.9
32.428.9
No. at risk:
De
ath
or
Dis
ab
ling
Str
oke
(%
)
Months
TAVR TF (none-trace PAR)
Surgery TF (none-trace PAR)
0
20
40
60
80
0 12 24 36 48 60
Primary Endpoint: 2-Yr Landmark Analysis
VI TF Population with None-Trace PAR
TAVRSurgery
Months
494 451 437 392 335 174555 491 469 413 359 191
![Page 30: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/30.jpg)
Flow Stagnation / Leaflet Thrombosis
Post-TAVR
Midha et al, Circulation 2017;136:1598-1609
![Page 31: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/31.jpg)
JAMA Network Open 2018
![Page 32: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/32.jpg)
Scenarios That May Require SAVR
• High risk for PVR (calcium in LVOT) or root
rupture
• Bicuspid valve and low risk with or without enlarged
aortic root
• Enlarged root (>4.5 cm or >5.5 cm) requiring
replacement
• Very young pts who want mechanical valves
• Aortic annulus area > 750mm
• Predominantly AI and very little AS
• Short annulus to STJ and worried about root
rupture
• Low coronaries although usually ok if root large
enough
![Page 33: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/33.jpg)
Shared decision making is not
patient education or informed consent
Patient Provider
1. Knowledge transfer
2. Patient preferences
3. Deliberation / consensus
Charles, Whelan, et al. 1999 Soc Sci Med
![Page 34: SAVR in the Era of TAVR Vinod H. Thourani, MD · 2020. 2. 25. · SAVR in the Era of TAVR Vinod H. Thourani, MD Bernie Marcus Chief of Cardiovascular Surgery Marcus Heart and Vascular](https://reader035.fdocuments.in/reader035/viewer/2022063018/5fdd16b03289dd0f4b3b004c/html5/thumbnails/34.jpg)
Conclusions
The growth in TAVR in the US has been
predominantly in intermediate-risk patients
Growth in the next 5 years will most likely be in the
low-risk population
Heart team decision-making should continue utilize
anatomic criteria for optimal patient outcomes
regardless for the procedure type (SAVR or TAVR)
In younger patients, more emphasis should be placed
on the most optimal procedure for long-term success
Share-decision making should be a mainstay of the
discussion with patients